

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 76989

**Title:** Treatment of refractory/relapsed extranodal NK/T cell lymphoma by decitabine plus anti-PD-1: a case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03982286

**Position:** Peer Reviewer

**Academic degree:** N/A

**Professional title:** N/A

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-04-13

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2022-05-18 06:52

**Reviewer performed review:** 2022-05-18 07:09

**Review time:** 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
-------------------------------------	---

### SPECIFIC COMMENTS TO AUTHORS

The authors show the N/K lymphoma treated with anti- PD-1 drug. The case is so interesting, however, I have some concerns to be discussed. 1. How about involvement of inflammatory markers such as IL-2, or IFN ? Please discuss citing the following article. (2021). Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas. European journal of histochemistry : EJH, 65(3), 3203. <https://doi.org/10.4081/ejh.2021.3203> 2. How do you think about mutual effect between NK cell and PD-1 positive cell? 3. Please show the SUV-max in Figure 1. 4. Please make more enrich the legends in Figure 2.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 76989

**Title:** Treatment of refractory/relapsed extranodal NK/T cell lymphoma by decitabine plus anti-PD-1: a case report

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05776275

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Research Associate

**Reviewer's Country/Territory:** United Kingdom

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-04-13

**Reviewer chosen by:** Dong-Mei Wang

**Reviewer accepted review:** 2022-05-25 11:08

**Reviewer performed review:** 2022-06-02 07:45

**Review time:** 7 Days and 20 Hours

Scientific quality	<input checked="" type="radio"/> Grade A: Excellent <input type="radio"/> Grade B: Very good <input type="radio"/> Grade C: Good <input type="radio"/> Grade D: Fair <input type="radio"/> Grade E: Do not publish
Language quality	<input checked="" type="radio"/> Grade A: Priority publishing <input type="radio"/> Grade B: Minor language polishing <input type="radio"/> Grade C: A great deal of language polishing <input type="radio"/> Grade D: Rejection
Conclusion	<input type="radio"/> Accept (High priority) <input type="radio"/> Accept (General priority) <input type="radio"/> Minor revision <input checked="" type="radio"/> Major revision <input type="radio"/> Rejection
Re-review	<input type="radio"/> Yes <input checked="" type="radio"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
-------------------------------------	---

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors have demonstrated the efficacy of the combination of decitabine and anti-PD-1. The manuscript lacks introduction (background information is lacking). The abstract lacks detail on the cohort & method.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 76989

Title: Treatment of refractory/relapsed extranodal NK/T cell lymphoma by decitabine plus anti-PD-1: a case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03982286

Position: Peer Reviewer

Academic degree: N/A

Professional title: N/A

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2022-04-13

Reviewer chosen by: Yu-Lu Chen

Reviewer accepted review: 2022-06-29 03:20

Reviewer performed review: 2022-06-29 03:20

Review time: 1 Hour

Scientific quality ☐ Grade A: Excellent ☒ Grade B: Very good ☐ Grade C: Good

☐ Grade D: Fair ☐ Grade E: Do not publish

Language quality ☒ Grade A: Priority publishing ☐ Grade B: Minor language polishing ☐ Grade C: A great deal of language polishing ☐ Grade D: Rejection

Conclusion ☒ Accept (High priority) ☐ Accept (General priority)

☐ Minor revision ☐ Major revision ☐ Rejection



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

Peer-reviewer statements    Peer-Review: ☒ Y] Anonymous    ☐ Onymous

Conflicts-of-Interest: ☐ Yes    ☒ Y] No

#### SPECIFIC COMMENTS TO AUTHORS

The authors replied well, so the manuscript is suitable for publication.

#### RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 76989

Title: Treatment of refractory/relapsed extranodal NK/T cell lymphoma by decitabine plus anti-PD-1: a case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05776275

Position: Peer Reviewer

Academic degree: PhD

Professional title: Research Associate

Reviewer's Country/Territory: United Kingdom

Author's Country/Territory: China

Manuscript submission date: 2022-04-13

Reviewer chosen by: Yu-Lu Chen

Reviewer accepted review: 2022-06-29 10:13

Reviewer performed review: 2022-06-30 01:02

Review time: 14 Hours

Scientific quality    ☒ Y] Grade A: Excellent    ☐ Grade B: Very good    ☐ Grade C:  
Good



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

☐ Grade D: Fair ☐ Grade E: Do not publish

Language quality ☐ Grade A: Priority publishing ☐ Grade B: Minor language  
polishing ☐ Grade C: A great deal of language polishing ☐ Grade D: Rejection

Conclusion ☐ Accept (High priority) ☐ Accept (General priority)

☐ Minor revision ☐ Major revision ☐ Rejection

Peer-reviewer statements Peer-Review: ☐ Anonymous ☐ Onymous

Conflicts-of-Interest: ☐ Yes ☐ No

#### SPECIFIC COMMENTS TO AUTHORS

The manuscript demonstrates the potential ability of decitabine combined with PD-1 inhibitor to treat R/R ENKL, thus providing a new treatment strategy.